Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gallstones during octreotide therapy.

R H Dowling1, S H Hussaini, G M Murphy

  • 1Gastroenterology Unit, UMDS of Guy's Hospital, London, England.

Metabolism: Clinical and Experimental
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

The New England journal of medicine·2000
Same author

Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment.

The Journal of clinical endocrinology and metabolism·2000
Same author

Complications of inferior petrosel sinus sampling.

The Journal of clinical endocrinology and metabolism·2000
Same author

'Gangliocytomas' of the pituitary: a heterogeneous group of lesions with differing histogenesis.

The American journal of surgical pathology·2000
Same author

Primary hyperaldosteronism (Conn syndrome): MR imaging findings.

Radiology·2000
Same author

Screening children at risk of developing inherited endocrine neoplasia syndromes.

Clinical endocrinology·2000

Octreotide treatment may increase gallbladder stone (GBS) risk. While often cholesterol-rich and dissolvable, some octreotide-associated GBS may be non-cholesterol based on CT scan analysis.

Area of Science:

  • Gastroenterology and Hepatology
  • Endocrinology
  • Pharmacology

Background:

  • Gallbladder stones (GBS) affect up to 50% of patients on octreotide, with variable reported prevalence.
  • Octreotide impairs meal-stimulated cholecystokinin (CCK) release, leading to gallbladder hypomotility.
  • Little is known about octreotide's effects on biliary cholesterol saturation, nucleation, and bile composition.

Purpose of the Study:

  • To investigate the incidence, composition, and pathogenetic mechanisms of GBS in patients treated with octreotide.
  • To explore the dissolvability and potential for primary prevention of octreotide-associated GBS.
  • To analyze GBS composition and predict dissolvability using CT scan attenuation values (Hounsfield Units).

Main Methods:

  • Review of existing literature on GBS prevalence and characteristics in octreotide-treated patients.

Related Experiment Videos

  • Analysis of GBS composition and CT scan attenuation values (Hounsfield Units) in a cohort of acromegalic patients.
  • Comparison of octreotide-associated GBS characteristics with general GBS pathophysiology and dissolvability criteria.

    • Main Results:

    • Most GBS are cholesterol-rich, radiolucent, and dissolvable with bile acid treatment.
    • Octreotide-associated GBS are often reported as cholesterol-rich and dissolvable.
    • Preliminary CT scan data in 11 acromegalic patients showed a wide range of Hounsfield Units (23-490), suggesting non-cholesterol stones in at least four patients.

    Conclusions:

    • Octreotide treatment is associated with an increased prevalence of GBS.
    • While many octreotide-associated GBS appear cholesterol-rich, CT scan findings suggest a subset may be non-cholesterol.
    • Further research is needed to fully elucidate the mechanisms and characteristics of octreotide-induced GBS.